栀子大黄汤在酒精性肝病小鼠模型中的保护作用  

Protective effect of Zhizi Dahuang decoction in a mouse model of alcoholic liver disease

作　　者：侯逸文 张荣杰 纪龙珊[1,2,3] 李茜 高月求 李曼[1,2,3] HOU Yiwen;ZHANG Rongjie;JI Longshan;LI Qian;GAO Yueqiu;LI Man(Cell Immunology Laboratory,Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China;Department of Hepatology,Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China;Key Laboratory of Liver and Kidney Diseases,Ministry of Education,Shanghai 201203,China)

机构地区：[1]上海中医药大学附属曙光医院细胞免疫实验室,上海201203 [2]上海中医药大学附属曙光医院肝病科,上海201203 [3]肝肾疾病病症教育部重点实验室,上海201203

出　　处：《临床肝胆病杂志》2023年第12期2873-2884,共12页Journal of Clinical Hepatology

基　　金：上海市炎癌转化病证生物学前沿科学研究基地(2021科技03-12);上海市中医临床重点实验室(20DZ2272200)。

摘　　要：目的 阐明栀子大黄汤(ZZDHT)通过改善肝脏中性粒细胞的氧化应激治疗酒精性肝病(ALD)的作用。方法 (1)运用网络药理学方法筛选ZZDHT的化学成分及其对应的作用靶点,分析其治疗ALD的潜在靶点和相关功能通路。(2)使用非靶代谢组学技术检测ZZDHT在小鼠血清和肝脏中代谢物变化情况,配制两倍中剂量浓度的ZZDHT予以灌胃,分别于灌胃后6个时间点(10 min、30 min、1 h、2 h、4 h、6 h)取小鼠血清和肝组织,混合进行后续质谱分析(用药组,18只)。对照组(18只)予以等量生理盐水灌胃。使用超高液相色谱技术,快速分离和鉴定ZZDHT在血清和肝组织中的代谢物,对ZZDHT有效成分进行验证。(3)8周龄C57BL/6J雄性小鼠随机均分为对照组、模型组、ZZDHT低剂量[ZZDHT(L)]组、ZZDHT中剂量[ZZDHT(M)]组、ZZDHT高剂量[ZZDHT(H)]组(每组10只),除对照组外,其余各组建立ALD小鼠模型(NIAAA模型小鼠),用药组在造模的同时分别进行ZZDHT低、中、高剂量的灌胃,对照组和模型组使用等量生理盐水灌胃。检测血清ALT、AST和TG的表达水平;PCR测得肝脏相关炎性、氧化应激和中性粒细胞指标基因表达水平;ELISA法测定血清中炎症和氧化应激相关指标;SOD、GSH-Px、MDA检测肝脏氧化应激水平;通过HE染色、MPO染色以及油红染色观察小鼠肝组织损伤、中性粒细胞浸润及脂质沉积情况。计量资料多组间比较采用单因素方差分析,进一步两两比较采用LSD-t检验。结果 (1)通过筛选共得到ZZDHT的53个有效活性成分,227个靶点基因,ALD的靶点基因共8 685个,两者共同的靶点基因222个。核心通路包括interleukin-6 signaling、TNF signaling pathway等。(2)非靶代谢分析得出ZZDHT在小鼠肝脏中代谢物有225个,在血清中代谢物有227个,共同代谢物有126个。分析得到肝脏代谢物核心通路有glycerolipid metabolism、inflammatory mediator regulation of TRP channels等,血清代谢物核心通路�Objective To investigate the effect of Zhizi Dahuang decoction(ZZDHT)in the treatment of alcoholic liver disease(ALD)by improving oxidative stress in hepatic neutrophils.Methods Network pharmacology was used to obtain the chemical components of ZZDHT and their corresponding action targets and analyze the potential targets and functional pathways of ZZDHT in the treatment of ALD.The non-target metabolomics technology was used to observe the changes in the metabolites of ZZDHT in mouse serum and liver.The mice were given ZZDHT at a dose twice as much as the middle dose concentration by gavage,and serum and liver samples were collected at six time points after gavage(10 minutes,30 minutes,1 hour,2 hours,4 hours,and 6 hours)and were then mixed for mass spectrometry(administration group with 18 mice),while the 18 mice in the control group were given an equal volume of normal saline by gavage.Ultra-performance liquid chromatography was used for rapid isolation and identification of the metabolites of ZZDHT in serum and liver tissue,and the effective constituents of ZZDHT were validated.Male C57BL/6J mice,aged 8 weeks,were randomly and equally divided into control group,model group,and low-,middle-,and high-dose ZZDHT groups,with 10 mice in each group.All mice except those in the control group were used to establish a mouse model of ALD(NIAAA model mice),and at the same time,the mice in the administration groups were given low-,middle-,and high-dose ZZDHT by gavage,while those in the control group and the model group were given an equal volume of normal saline by gavage.The serum levels of alanine aminotransferase(ALT),aspartate aminotransferase(AST),and triglyceride(TG)were measured;PCR was used to measure the gene expression levels of related inflammation,oxidative stress,and neutrophil indicators in the liver;ELISA was used to measure the levels of related inflammation and oxidative stress indicators in serum;superoxide dismutase(SOD),glutathione peroxidase(GSHPx),and malondialdehyde(MDA)were measured to observe the

关 键 词：肝疾病 酒精性 栀子大黄汤 氧化性应激 模型 动物 

分 类 号：R285.5[医药卫生—中药学]